- CFO Spotlights
- Profiles
- John P. Sharp
Profile
John P. Sharp
Interim Chief Financial Officer, Cadrenal Therapeutics, Inc.
In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.
John P. Sharp has been Interim Chief Financial Officer of Cadrenal Therapeutics, Inc. since June 25, 2026, according to the company's filing of June 29, 2026.1
The filing gives John P. Sharp's previous role as Senior Director at Lohman & Associates.1 John P. Sharp joined from outside Cadrenal Therapeutics, Inc., by the record's reading of the filing.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) Pharmaceutical Preparations | Interim Chief Financial Officer | In the seat, on an interim basis |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- June 25, 2026effective
Cadrenal Therapeutics, Inc. named John P. Sharp Interim Chief Financial Officer, effective June 25, 2026. Profile of Quang X. Pham.
Sharp as Interim Chief Financial Officer of the Company.
[1] Filing by Cadrenal Therapeutics, Inc., filed with the SEC on June 29, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Cadrenal Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 29, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or John P. Sharp wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.